‘Transformational' new breast cancer drug could halt the growth of tumours
A new drug has been shown to halt the growth of certain breast cancer tumours, potentially delaying the need for chemotherapy, according to a new study.
The Serena-6 trial found that camizestrant is effective in stopping cancer cells from using hormones to grow. One professor described the drug as representing "a pivotal moment in breast cancer care".
Scientists said the trial marked the first global study demonstrating that early detection of cancer resistance through blood tests can significantly benefit patients.
The study focused on patients with hormone-positive, HER2-negative breast cancer, which accounts for approximately 70 per cent of all cases. The results indicated that patients treated with camizestrant experienced a 56 per cent reduction in cancer progression compared to those receiving standard therapies.
Doctors used a blood test to identify changes in the cancer's DNA, which signal the potential failure of current treatments. Upon detecting these signs, some patients were administered camizestrant, while others continued with their standard treatment.
Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others.
The drug was safe for most patients but 1 per cent stopped taking it because of side effects.
More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London.
Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'.
Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.'
About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said.
The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday.
Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment.
'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow.
'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions.
'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
4 hours ago
- Daily Mail
Scientists reveal how humans will have superpowers by 2030
By 2030, rapid technological advancements are expected to reshape humanity, unlocking abilities once confined to science fiction—from superhuman strength to enhanced senses. Robotic exoskeletons may soon allow people to lift heavy objects with ease, while AI-powered wearables, such as smart glasses and earbuds, could provide real-time information and immersive augmented reality experiences. Healthcare may be revolutionized by microscopic nanobots capable of repairing tissue and fighting disease from within the bloodstream, potentially extending human lifespans. Developers are also working on contact lenses with infrared vision and devices that allow users to "feel" digital objects, paving the way for entirely new ways to experience the world. Tech pioneers like former Google engineer Ray Kurzweil believe these innovations are early steps toward the merging of humans and machines, with brain-computer interfaces offering direct access to digital intelligence. While many of these breakthroughs are already in progress, others remain in the experimental phase, facing significant technical and ethical challenges, including concerns about privacy and safety. Still, some of these futuristic technologies may become reality within the next five years, with the potential to enhance human strength, cognition, and perception in ways never before possible. Superhuman strength Kurzweil, a self-proclaimed futurist, has claimed that the foundation of human immortality will begin in 2030, with man set to merge with machines by 2045. By 2030, robotic exoskeletons could give human beings super strength, either by enabling feats like lifting huge objects in factories or making soldiers stronger on the battlefield. US-based robotics company Sarcos Robotics has already demonstrated a robotic exoskeleton that has a 'strength gain' ratio of 20-to-one. This means that normal people can carry weights of up to 200 pounds over an extended period of time. The suit took 17 years and $175 million to develop. Other exoskeletons, such as German Bionic's 'Exia' exoskeleton, incorporate AI that learns from the wearer's movement, enabling them to lift huge weights without feeling tired. These exoskeletons are already being used by staff in German hospitals. Super-healing and immortality In five years, humans could have tiny 'nanobots' in their bloodstream to keep them healthy, meaning people could recover rapidly from injury and even from diseases such as cancer. Kurzweil has claimed that by 2029, artificial intelligence will become 'superhuman' and that will allow for more technological breakthroughs to follow rapidly. One of the upcoming breakthroughs, according to Kurzweil, will be the development of microscopic nanobots that operate within the bloodstream, maintaining health without the need for constant medical monitoring. In his latest book, The Singularity Is Nearer, Kurzweil forecasts a dramatic transformation in human life after 2029, with essential goods becoming more affordable and people beginning to merge with machines through technologies like brain-computer interfaces, similar to Elon Musk's Neuralink. He also pointed to recent advances in artificial intelligence, including tools like ChatGPT, as evidence that his 2005 predictions are on track, stating that "the trajectory is clear." Super vision Contact lenses that enable wearers to see huge distances or even to beam computer information directly into their eyes could be on sale by 2030. Scientists in China recently developed contact lenses that allow wearers to see in the dark. The new lenses allow wearers to see infrared light, without requiring bulky night-vision goggles. Professor Tian Xue, at the University of Science and Technology of China, said he hopes his work could inspire scientists to create contact lenses that offer people 'super vision.' Enhanced senses Devices that give humans enhanced senses could be on the market, with research by Ericsson, a Swedish multinational networking and telecommunications company, suggesting that digital wristbands could soon give anyone the ability to 'feel' digital objects. Pioneering 'cyborg' designers have already tested devices that give people superhuman senses. Entrepreneur, transhumanist, and self-described cyborg Liviu Babitz created 'Northsense,' which allowed him to sense when he faces magnetic north. Manel Munoz, founder of the Trans Species Society, implanted two 'fins' on top of his head, which enabled him to 'hear' the weather. The sound is transmitted through his skull by bone conduction. Munoz has said he hears the weather through the 'sound of bubbles.' Knowing everything instantly with digital wearables By 2030, AI-enhanced wearables such as earbuds could enable everyone to plug into 'digital superpowers,' with everyone able to receive answers instantly. Meta is already adding AI to Ray-Ban glasses, and Google is designing an operating system for XR (augmented reality and virtual reality). Computer scientist Louis Rosenberg has said that these abilities will emerge from the convergence of AI, augmented reality, and conversational computing. 'They will be unleashed by context-aware AI agents that are loaded into body-worn devices that see what we see, hear what we hear, experience what we experience, and provide us with enhanced abilities to perceive and interpret our world,' Rosenberg explained. 'I refer to this new technological direction as augmented mentality and I predict that by 2030, a majority of us will live our lives with context-aware AI agents bringing digital superpowers into our daily experiences.'
Telegraph
8 hours ago
- Telegraph
NHS sends patients abroad after waiting lists hit record high
The NHS is paying to send rising numbers of British patients abroad for treatment after waiting lists in England hit record highs. The health service is funding treatments across Europe in countries including Poland, Lithuania and the Czech Republic. Treatments being carried out abroad range from routine operations, including hip replacements and cataract operations, to more complex cancer surgery. The number of people having such procedures overseas has jumped by 42 per cent in just two years, The Telegraph can reveal. The Health Secretary described the situation as 'unacceptable', saying a 'broken NHS' had left patients waiting 'far too long for treatment, forcing many to go private or even seek healthcare abroad'. The revelations come as Wes Streeting prepares to publish a 10-year health plan that aims to clear backlogs and reform the way services are delivered. On Friday night, he pledged his plan would 'catapult the NHS into the 21st century and get people seen on time in a modern health service on British shores'. Experts said the rising cases were a 'terrible indictment' of the state of the NHS, with Poland, Germany, Italy and Belgium among the main beneficiaries. Under a little-known post-Brexit healthcare agreement, the NHS will pay another European country to treat UK patients where there is 'undue delay' to them accessing equivalent treatment on the NHS within a 'medically acceptable timeframe'. Patients desperate to have gynaecology surgery and hip replacements were the most likely to get NHS approval to travel overseas for their treatment. Those waiting for cancer treatment, and surgery to repair hernias, remove gallbladders and treat cataracts also fled Britain to get help more quickly, the investigation reveals. The treatment or surgery must be provided by a state healthcare system, not a private clinic, and patients must fund their own travel and accommodation costs. There has been a rapid rise in the number of UK patients using the scheme, as the NHS battles to reduce waiting lists, which peaked in 2023. In the last three years, the NHS has spent £4.32 million sending 352 patients overseas for treatment, according to data from the NHS Business Services Authority, which handles the payments. The number of overseas treatments paid for by the NHS jumped from 99 in 2022-23 to 112 in 2023-24 and rose again to 141 in 2024-25, according to figures obtained by The Telegraph under Freedom of Information laws. Mr Streeting said: 'This Government inherited a broken NHS, with patients left waiting far too long for treatment, forcing many to go private or even seeking healthcare abroad. This is unacceptable and, since day one in office, we have been delivering the investment and reform needed to turn the NHS around. 'We are focused on delivering for patients, so they get the treatment they need, when they need it, closer to home. In less than a year, we've delivered 3.6 million more appointments, cut the waiting list by almost a quarter of a million, and diagnosed an extra 100,000 suspected cancer patients on time. 'There's a long way to go, but we are finally putting the NHS on the road to recovery. 'Our forthcoming 10-year plan will lay out how we catapult the NHS into the 21st century and get people seen on time in a modern health service on British shores.' Dennis Reed, from Silver Voices, said: 'This is a terrible indictment of the state of the NHS. People have to be desperate to think about having hospital treatment in another country, hundreds of miles away. 'It is really worrying and it's also worrying about the inequalities – most of us wouldn't know about this scheme, and many could not afford the travel and hotels, so the vast majority of the population just have to put up with really long waits.' 'Says a lot about pressures on NHS' There are currently 1.4 million people waiting for NHS gynaecology or orthopaedic procedures, including hip replacements, in England. Of these, nearly 43,000 have waited more than a year for treatment since being diagnosed, latest figures for April 2025 show. Siva Anandaciva, director of policy at The King's Fund, said it was 'striking' that more Britons were getting treatment overseas. 'It was only a few years ago that the concerns about medical tourism were that too many people were coming to the UK to seek treatment. It says a lot about the pressures the NHS is under that the concern now is that too many people [from the UK] are seeking treatment overseas,' he said. 'The NHS has made substantial progress in tackling the very longest waits for care that built up before and after the Covid-19 pandemic, but the reality is that it will be several years before national waiting list targets are routinely met again.' Patients were most likely to travel to Poland for treatment, with the NHS paying for 72 procedures to be carried out there between 2022-23 and 2024-25. This was followed by Germany (59 procedures), Italy (32), Belgium (31) and Ireland (26). But the NHS spent the most money on treatments performed in Ireland, which cost around £3.15 million over the last three years. It also spent £224,000 on NHS patients having treatment in Germany; £147,000 on treatments in Poland; £138,000 in Switzerland; £138,000 in Italy; and £134,000 in Austria. Payment figures were recorded by the NHS in the local currency and converted to pound sterling by The Telegraph based on currency exchange rates at the time of writing. Separate NHS England figures also revealed that nearly two out of every five applications (37 per cent) made by patients wanting to travel abroad for treatment were approved in 2024, up from just one in five (21 per cent) in 2022, suggesting more applications are meeting the criteria for 'undue delay'. Rachel Power, chief executive of The Patients Association, said when patients felt compelled to seek treatment abroad, it was 'a reflection of the state of the waiting lists and the very severe problems of the NHS'. Mrs Power suggested the system could worsen 'inequalities', as the scheme is only accessible to those able to work out the application process and who have the means to pay for travel and accommodation. 'To do this, you have to have the confidence and ability to navigate the system – we talk to patients all the time who can't navigate and access treatment [on the NHS],' she said. Prof Ranee Thakar, president of the Royal College of Obstetricians and Gynaecologists, said the fact patients were travelling long distances for treatment was 'clear evidence that they can't access the care they need, when they need it'. She added the Government must tackle the 'critical issue' of long waits for gynaecology treatment in its upcoming NHS 10-year health plan. 'There are more than three quarters of a million women in the UK waiting for hospital gynaecology care, with serious conditions that have a devastating impact on almost every aspect of their lives,' said Prof Thakar.
Daily Mail
14 hours ago
- Daily Mail
Study pinpoints exact number of coffees per day that can cut the risk of sudden cardiac death
A coffee a day might be enough to keep the doctor away. For US researchers have found coffee lovers tend to have healthier hearts, putting them at lower risk of cardiac death. And the benefits can be achieved by drinking just one cup a day, they claimed—but only if they drink it black. Those who drank between two to three cups, however, saw the most benefits, slashing their risk by almost a fifth. The findings, from the study of more than 46,000 people, add to the growing body of evidence highlighting the drink's health benefits. Professor Fang Fang Zhang, a nutrition expert at Tufts University in Boston, said: 'Coffee is among the most-consumed beverages in the world, and with nearly half of American adults reporting drinking at least one cup per day, it's important for us to know what it might mean for health.' Some research has already linked coffee to reducing the risk of heart disease, heart failure and strokes, while other studies report it prolongs life. But medics remain divided, warning that excessive amounts of coffee—packed full of caffeine—can actually damage the heart. The new study, in The Journal of Nutrition, tracked the daily coffee consumption of 46,332 people over the age of 20. Over a follow up of 11 years, they found black coffee and coffee with low levels of added sugar and saturated fat—like milk or cream—had a 14 per cent lower risk of death compared to no coffee consumption. But one cup of black coffee a day, specifically, slashed the risk of death including cardiovascular death, by 16 per cent. Those who drank between two and three a day saw the risk lowered by 17 per cent. However, researchers noted that the benefits peaked at three cups a day. They also found that those who added high amounts of sweeteners and dairy to their coffee did not experience the same benefits. Researchers acknowledged, however, that the coffee consumption was self-reported by volunteers, so may have been underreported, limiting the findings. It was also assessed without detailing the roast used and preparation methods. NHS data shows a rise in the number of younger adults suffering from heart attacks over the past decade. The biggest increase (95 per cent) was recorded in the 25-29 year-old demographic, though as numbers of patients are low even small spikes can look dramatic Under NHS guidance, consuming more than four cups a day can increase blood pressure. Around 2million people in the UK are diagnosed with some form of heart disease, according to Government figures. But charities estimate that a further six million have undiagnosed high blood pressure—one of the leading risk factors for stroke and heart attack. Heart disease describes a range of conditions that affect the heart and blood vessels. It's often caused by fatty deposits in the arteries that can make it harder for blood and oxygen to flow properly through the vessels and to and from the heart. This increases the risk of a blockage, and therefore stroke or heart attack. Last year, alarming data revealed that premature deaths from cardiovascular problems, such as heart attacks and strokes, had hit their highest level in more than a decade. MailOnline has previously highlighted how the number of young people, under 40, in England being treated for heart attacks by the NHS is on the rise. Cases of heart attacks, heart failure and strokes among the under-75s has tumbled since the 1960s thanks to plummeting smoking rates, advanced surgical techniques and breakthroughs such as stents and statins. But now, rising obesity rates, and its catalogue of associated health problems such as high blood pressure and diabetes, are thought to be one of the major contributing factors.
